However, a group of therapies known as SGLT2 inhibitors did not show statistically significant benefit in preventing heart attack or strokes in patients diagnosed with cardiovascular disease.
People with diabetes have a high risk of cardiovascular disease, so cardiovascular drugs benefit from the important interests of doctors and patients.
Stephen Wiviott of Brigham and Boston Women's Hospital found that this finding was important in making a clear picture of the SGLT2 drug in patients with severe diagnoses.
AstraZeneca hopes that new data will help extend the use of Farxiga to a broad range of patients.
The primary results of the 17,000-patient clinical trial presentation were first published in September, but details were published on Saturday at the American Heart Association annual meeting and published in the New England Journal of Medicine.
These results show that Farxiga reduces the risk of hospitalization for heart disease and the risk of kidney disease by 27%.
Dr. Wiviott said that although two smaller studies on competing SGLT2 drugs focused on patients diagnosed with heart disease, the overall picture of the study, declared, is that a broad prevention of heart attack is a major benefit.
"The main benefit of cardiovascular medication when analyzing these three studies is to reduce heart attack," Prof Wiviott said.
Diabetes scholars have focused primarily on reducing blood sugar levels to a certain level for decades. However, diabetic patients' trends for other problems such as heart attack with a 5-year survival rate of only 50% suggest a more holistic approach is needed.
"There is a message that the current way of lowering our glucose level may be as important as the rate we do," the doctor said, "we should choose drugs that improve the patient's average life span, as well as drugs that are effective in lowering blood sugar." .
Farxiga already competes with competitive SGLT2 drugs such as Eli Lilly and Jardiance produced by Boehringer Ingelheim, Invokana Johnson & Johnson. They show an average life expectancy for patients who have already been diagnosed with heart problems, ie secondary prevention.
After evaluating patients who were not diagnosed with cardiovascular disease in the AstraZeneca trial, this study opened up a broader market, including primary prevention.
The Declare study did not confirm that the risk of amputation, fracture, bladder or gross cancer was not increased in patients treated with Farxiga. Sometimes observed in patients treated with SGLT is an increased risk of genital infection.